BioCentury | Oct 30, 2020
Distillery Therapeutics

KSP as a neuroblastoma target

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Inhibiting the mitotic kinesin KSP could treat neuroblastoma, a pediatric sympathetic nervous system malignancy. In neuroblastoma patients, high KSP expression in tumors was associated with high-risk neuroblastoma, advanced tumor...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Targeting the NMDA receptor-TRPM4 complex for neurodegeneration

DISEASE CATEGORY: Neurology INDICATION: Stroke; neurology Disruption of the NMDA receptor-TRPM4 complex could treat ischemic stroke and other neurodegenerative diseases with NMDA receptor involvement. In mouse hippocampal neurons deprived of oxygen and glucose or treated...
BioCentury | Oct 27, 2020
Distillery Therapeutics

PCF11 binding site on E3 ubiquitin ligase MAGEA11 identified as neuroblastoma target

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Interrupting the interaction between the oncogenic E3 ubiquitin ligase MAGEA11 and its substrate PCF11 could treat neuroendocrine tumors. Crystallographic analysis of the MAGEA11-PCF11 complex identified a shallow cleft on...
BioCentury | Oct 27, 2020
Distillery Therapeutics

UCSF team develops trivalent binder of SARS-CoV-2 spike for COVID-19

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus A UCSF team led by Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) founder Jim Wells has developed a trivalent immunoglobulin variable heavy domain-based inhibitor of the ACE2-SARS-CoV-2 S interaction that could treat COVID-19 infection....
BioCentury | Sep 10, 2020
Product Development

BioNTech, Pfizer complete exploratory talks with the European Commission for 200M COVID-19 vaccine doses

BioNTech, Pfizer vaccine to supply vaccine to EUOn Wednesday, BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) became the sixth group of COVID-19 vaccine developers to complete exploratory talks on...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting the PP2A-STRN3 interaction to treat gastric cancer

DISEASE CATEGORY: Cancer INDICATION: Gastric cancer Interrupting the interaction between PP2A catalytic subunit PPP2CA and STRN3, a regulatory subunit, could treat gastric cancer. In patients, STRN3 expression...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with a camelid-derived antibody platform and its first to deploy the technology as a countermeasure against pandemic threats. ExeVir, which...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Scripps mAb shows signs of COVID-19 protection in hamsters

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus A team led by Scripps Research Institute researchers has identified an anti-spike mAb that could treat COVID-19. High throughput screening of 2,045 antibodies derived from eight donors, who previously...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Promoting degradation of the MDM2 oncogene for liposarcoma

DISEASE CATEGORY: Cancer INDICATION: Sarcoma A pyrido-indole-based tool compound that triggers degradation of MDM2, an enzyme that suppresses p53 expression, could treat liposarcoma. In 10 human liposarcoma cell lines, the compound inhibited growth with IC...
BioCentury | Jun 23, 2020
Distillery Therapeutics

Repurposing antimalarial drug lumefantrine for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer The antimalarial drug lumefantrine, an FLI1 inhibitor, could treat glioblastoma resistant to radiation and temozolomide. A cell-based screen of compounds structurally related to approved and unapproved treatments for Ewing...
Items per page:
1 - 10 of 1374